Acute myocardial infarction

Active Ingredient: Metoprolol

Indication for Metoprolol

Population group: only adults (18 years old or older)
  • Early intervention of metoprolol tartrate in acute myocardial infarction reduces infarct size and the incidence of ventricular fibrillation. Pain relief may also decrease the need for opiate analgesics.
  • Long-term prophylaxis after recovery from acute myocardial infarction.

For this indication, competent medicine agencies globally authorize below treatments:

50-200 mg in 3-4 divided doses daily

Route of admnistration

Oral

Defined daily dose

50 - 200 mg

Dosage regimen

From 12.5 To 50 mg 4 time(s) per day every day

Loading dose

50 mg

Detailed description

Early intervention: Orally, therapy should commence 15 minutes after the last intravenous injection with 50mg every 6 hours for 48 hours and preferably within 12 hours of the onset of chest pain. Patients who fail to tolerate the full i.v. dose should be given half the suggested oral dose.

Maintenance: The usual maintenance dose is 200 mg daily given in divided doses. The treatment should be continued for at least 3 months.

5-15 mg

Route of admnistration

Intravenous

Defined daily dose

5 - 15 mg

Dosage regimen

From 5 To 15 mg once every day

Detailed description

Intravenous metoprolol should be initiated in a coronary care or similar unit when the patient’s haemodynamic condition has stabilised. Therapy should commence with 5 mg I.V. every 2 minutes to a maximum of 15 mg total as determined by blood pressure and heart rate. The second or third dose should not be given if the systolic blood pressure is <90 mmHg, the heart rate is <40 beats/min and the P-Q time is >0.26 seconds, or if there is any aggravation of dyspnoea or cold sweating. Oral therapy should commence 15 minutes after the last injection with 50 mg every 6 hours for 48 hours. Patients who fail to tolerate the full intravenous dose should be given half the suggested oral dose.

Active ingredient

Metoprolol

Metoprolol is a cardioselective beta-adrenergic blocking agent. It has a relatively greater blocking effect on beta1-receptors (ie those mediating adrenergic stimulation of heart rate and contractility and release of free fatty acids from fat stores) than on beta2-receptors, which are chiefly involved in broncho and vasodilation.

Read more about Metoprolol

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.